Cargando…

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

BACKGROUND: Patients diagnosed with melanoma frequently search the internet for treatment information, including novel and complex immunotherapy. However, health literacy is limited among half of the German population, and no assessment of websites on melanoma treatment has been performed so far. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Brütting, Julia, Steeb, Theresa, Reinhardt, Lydia, Berking, Carola, Meier, Friedegund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315239/
https://www.ncbi.nlm.nih.gov/pubmed/30545808
http://dx.doi.org/10.2196/10676
_version_ 1783384246869557248
author Brütting, Julia
Steeb, Theresa
Reinhardt, Lydia
Berking, Carola
Meier, Friedegund
author_facet Brütting, Julia
Steeb, Theresa
Reinhardt, Lydia
Berking, Carola
Meier, Friedegund
author_sort Brütting, Julia
collection PubMed
description BACKGROUND: Patients diagnosed with melanoma frequently search the internet for treatment information, including novel and complex immunotherapy. However, health literacy is limited among half of the German population, and no assessment of websites on melanoma treatment has been performed so far. OBJECTIVE: The aim of this study was to identify and assess the most visible websites in German language on melanoma immunotherapy. METHODS: In accordance with the common Web-based information-seeking behavior of patients with cancer, the first 20 hits on Google, Yahoo, and Bing were searched for combinations of German synonyms for “melanoma” and “immunotherapy” in July 2017. Websites that met our predefined eligibility criteria were considered for assessment. Three reviewers independently assessed their quality by using the established DISCERN tool and by checking the presence of quality certification. Usability and reliability were evaluated by the LIDA tool and understandability by the Patient Education Materials Assessment Tool (PEMAT). The Flesch Reading Ease Score (FRES) was calculated to estimate the readability. The ALEXA and SISTRIX tools were used to investigate the websites’ popularity and visibility. The interrater agreement was determined by calculating Cronbach alpha. Subgroup differences were identified by t test, U test, or one-way analysis of variance. RESULTS: Of 480 hits, 45 single websites from 30 domains were assessed. Only 2 website domains displayed a German quality certification. The average assessment scores, mean (SD), were as follows: DISCERN, 48 (7.6); LIDA (usability), 40 (2.0); LIDA (reliability), 10 (1.6); PEMAT, 69% (16%); and FRES, 17 (14), indicating mediocre quality, good usability, and understandability but low reliability and an even very low readability of the included individual websites. SISTRIX scores ranged from 0 to 6872 and ALEXA scores ranged from 17 to 192,675, indicating heterogeneity of the visibility and popularity of German website domains providing information on melanoma immunotherapy. CONCLUSIONS: Optimization of the most accessible German websites on melanoma immunotherapy is desirable. Especially, simplification of the readability of information and further adaption to reliability criteria are required to support the education of patients with melanoma and laypersons, and to enhance transparency.
format Online
Article
Text
id pubmed-6315239
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-63152392019-01-28 Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis Brütting, Julia Steeb, Theresa Reinhardt, Lydia Berking, Carola Meier, Friedegund JMIR Cancer Original Paper BACKGROUND: Patients diagnosed with melanoma frequently search the internet for treatment information, including novel and complex immunotherapy. However, health literacy is limited among half of the German population, and no assessment of websites on melanoma treatment has been performed so far. OBJECTIVE: The aim of this study was to identify and assess the most visible websites in German language on melanoma immunotherapy. METHODS: In accordance with the common Web-based information-seeking behavior of patients with cancer, the first 20 hits on Google, Yahoo, and Bing were searched for combinations of German synonyms for “melanoma” and “immunotherapy” in July 2017. Websites that met our predefined eligibility criteria were considered for assessment. Three reviewers independently assessed their quality by using the established DISCERN tool and by checking the presence of quality certification. Usability and reliability were evaluated by the LIDA tool and understandability by the Patient Education Materials Assessment Tool (PEMAT). The Flesch Reading Ease Score (FRES) was calculated to estimate the readability. The ALEXA and SISTRIX tools were used to investigate the websites’ popularity and visibility. The interrater agreement was determined by calculating Cronbach alpha. Subgroup differences were identified by t test, U test, or one-way analysis of variance. RESULTS: Of 480 hits, 45 single websites from 30 domains were assessed. Only 2 website domains displayed a German quality certification. The average assessment scores, mean (SD), were as follows: DISCERN, 48 (7.6); LIDA (usability), 40 (2.0); LIDA (reliability), 10 (1.6); PEMAT, 69% (16%); and FRES, 17 (14), indicating mediocre quality, good usability, and understandability but low reliability and an even very low readability of the included individual websites. SISTRIX scores ranged from 0 to 6872 and ALEXA scores ranged from 17 to 192,675, indicating heterogeneity of the visibility and popularity of German website domains providing information on melanoma immunotherapy. CONCLUSIONS: Optimization of the most accessible German websites on melanoma immunotherapy is desirable. Especially, simplification of the readability of information and further adaption to reliability criteria are required to support the education of patients with melanoma and laypersons, and to enhance transparency. JMIR Publications 2018-12-13 /pmc/articles/PMC6315239/ /pubmed/30545808 http://dx.doi.org/10.2196/10676 Text en ©Julia Brütting, Theresa Steeb, Lydia Reinhardt, Carola Berking, Friedegund Meier. Originally published in JMIR Cancer (http://cancer.jmir.org), 13.12.2018. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cancer, is properly cited. The complete bibliographic information, a link to the original publication on http://cancer.jmir.org/, as well as this copyright and license information must be included.
spellingShingle Original Paper
Brütting, Julia
Steeb, Theresa
Reinhardt, Lydia
Berking, Carola
Meier, Friedegund
Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
title Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
title_full Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
title_fullStr Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
title_full_unstemmed Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
title_short Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis
title_sort exploring the most visible german websites on melanoma immunotherapy: a web-based analysis
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315239/
https://www.ncbi.nlm.nih.gov/pubmed/30545808
http://dx.doi.org/10.2196/10676
work_keys_str_mv AT bruttingjulia exploringthemostvisiblegermanwebsitesonmelanomaimmunotherapyawebbasedanalysis
AT steebtheresa exploringthemostvisiblegermanwebsitesonmelanomaimmunotherapyawebbasedanalysis
AT reinhardtlydia exploringthemostvisiblegermanwebsitesonmelanomaimmunotherapyawebbasedanalysis
AT berkingcarola exploringthemostvisiblegermanwebsitesonmelanomaimmunotherapyawebbasedanalysis
AT meierfriedegund exploringthemostvisiblegermanwebsitesonmelanomaimmunotherapyawebbasedanalysis